Analysis of prognostic factors of the first relapsed/refractory primary central nervous system lymphoma
10.3969/j.issn.1000-8179.2018.19.751
- VernacularTitle:首次复发 难治原发性中枢神经系统淋巴瘤预后影响因素分析
- Author:
Yan HUANG
1
;
Bobin CHEN
;
Pei LI
;
Yan YUAN
;
Yan MA
;
Tianling DING
;
Yixia WANG
;
Xiaoping XU
Author Information
1. 复旦大学附属华山医院血液科
- Keywords:
relapse;
refractory;
primary central nervous system lymphoma (PCNSL);
prognosis
- From:
Chinese Journal of Clinical Oncology
2018;45(19):985-993
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the clinical characteristics of patients with relapsed/refractory primary central nervous system lym-phoma (PCNSL) and to explore the factors that influence the prognosis, in order to provide evidence for the clinical diagnosis and treat-ment. Methods: Sixty-four patients with relapsed/refractory PCNSL diagnosed from October 2006 to August 2015 were selected. The clinical features, treatment plans, and laboratory examination data were retrospectively analyzed. Cox regression was used for multi-variate analysis. Results: Univariate and multivariate analyses showed that progression-free survival of first time (PFS1)≤1 year and Kar-nofsky performance status (KPS) score<70 points were independent prognostic factors in patients with first relapsed/refractory PCNSL. The median PFS2 and overall survival of second time (OS2) were 19 and 21 months, respectively, in patients with PFS1≥1 year, where-as the median progression free survival of second time (mPFS2) and OS2 were 10 and 14 months, respectively, in patients with PFS1<1 year. The median PFS2 (mPFS2) in patients with first relapse/refractory KPS score≥70 points and those with KPS score<70 points were 40 and 10 months, respectively, and the median OS2 were 43 and 12 months, respectively. The median PFS for the methotrexate (MTX) and non-MTX groups was 18 and 10 months, respectively. Multivariate analysis showed that the salvage therapy was a relevant factor influencing the patient's PFS. However, univariate analysis showed that the median OS2 in the MTX and non-MTX groups was 23 and 12 months, respectively, with significant difference but without any correlation with prognosis. Conclusions: progression-free sur-vival (PFS)≤1 year and KPS score<70 were independent prognostic factors in patients with first relapsed/refractory PCNSL. Patients with relapsed/refractory PCNSL who continuously received high-dose MTX-based treatment may have improved long-term treatment outcomes.
